October 29, 2021 -- Signet Therapeutics has raised $10 million in a financing round led by 5Y Capital (Morningside Venture), with participation from Yael Capital, Blue Ocean Capital, and existing investors Tiantu Capital and Sky9 Capital.
The money will go toward advancing the company's two oncology programs to clinical trials. In addition, Signet said it plans to expand its platform of disease models to other cancer areas and enable target discovery and pharmacodynamics studies at other pharmaceutical companies on a greater scale.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
